Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florquinitau F18 - Lantheus Cerveau

Next Previous
X
Search
Drug Profile

Florquinitau F18 - Lantheus Cerveau

Alternative Names: [18F]MK 6240; [18F]MNI-946; [F-18]MK-6240; Fluorine 18 MK 6240 - Lantheus Cerveau; Fluorine-18-MK6240; MK-6240; MK-6240 SUVR; XTR006

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerveau Technologies; Merck Sharp & Dohme
  • Developer Johnson & Johnson Innovative Medicine; Lantheus Cerveau; Merck Sharp & Dohme; Sinotau Pharmaceuticals; Washington University School of Medicine
  • Class Amines; Diagnostic agents; Imaging agents; Isoquinolines; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Neurodegenerative disorders

Most Recent Events

  • 10 Jan 2024 Sinotau Pharmaceutical completes a Clinical trial in Alzheimer's disease (In volunteers, Diagnosis) in China (IV) (NCT06151808)
  • 10 Jan 2024 Sinotau Pharmaceutical completes a phase I trial in Alzheimer's disease (In volunteers, Diagnosis) in China (IV) (NCT06151795)
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top